Treatment inferred disease severity in Crohn's disease: Evidence for a European gradient of disease course

Scandinavian Journal of Gastroenterology

Volumn 42, Issue 3, 2007, Pages 333-344

  Wolters, Frank L ^a   Joling, Catelijne ^b   Russel, Maurice G ^c   Sijbrandij, Jildou ^d   De Bruin, Marion ^a   Odes, Selwyn ^e   Riis, Lene ^f   Munkholm, Pia ^f   Bodini, Paolo ^g   Ryan, Barbara ^h   O'Morain, Colm ^h   Mouzas, Ioannis A ⁱ   Tsianos, Epameinondas ^j   Vermeire, Severine ^k   Monteiro, Estela ^l   Limonard, Charles ^d   Vatn, Morten ^m   Fornaciari, Giovanni ⁿ   Rodriguez, Dolores ^o   Groot, Wim ^b   Moum, Bjørn ^p   Stockbrügger, Reinhold W ^a   more..

^a MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^b MAASTRICHT UNIVERSITY   (Netherlands)

^c MEDISCH SPECTRUM TWENTE   (Netherlands)

^d MEMIC   (Netherlands)

^e BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

^f UNIVERSITY OF COPENHAGEN   (Denmark)

^g CREMONA HOSPITAL   (Italy)

^h ADELAIDE AND MEATH HOSPITAL   (Ireland)

ⁱ UNIVERSITY HOSPITAL OF HERAKLION   (Greece)

^j UNIVERSITY OF IOANNINA   (Greece)

^k UNIVERSITY OF LEUVEN   (Belgium)

^l HOSPITAL DE SANTA MARIA   (Portugal)

^m UNIVERSITY OF OSLO   (Norway)

ⁿ Arcispedale S Maria Nuova ^*  (Italy)

^o UNIVERSITY HOSPITAL COMPLEX OF VIGO   (Spain)

^p Østfold Hospital   (Norway)

more..

Author keywords

Crohn's disease; Disease outcome; Phenotype; Treatment

Indexed keywords

AZATHIOPRINE; CIPROFLOXACIN; CORTICOSTEROID; CYCLOSPORIN A; MERCAPTOPURINE; MESALAZINE; METHOTREXATE; METRONIDAZOLE;

ADULT; ANTIBIOTIC THERAPY; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; CORTICOSTEROID THERAPY; CROHN DISEASE; DISEASE CLASSIFICATION; DISEASE COURSE; FEMALE; GEOGRAPHIC DISTRIBUTION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; MAJOR CLINICAL STUDY; MALE; PHENOTYPE; POPULATION RESEARCH; PREDICTION; PRIORITY JOURNAL; RISK FACTOR; SURVIVAL; TOPICAL TREATMENT; TREATMENT OUTCOME;

ADULT; AGE DISTRIBUTION; AGE FACTORS; CONFOUNDING FACTORS (EPIDEMIOLOGY); CROHN DISEASE; EUROPE; FEMALE; FOLLOW-UP STUDIES; HEALTH TRANSITION; HUMANS; MALE; PHENOTYPE; PREDICTIVE VALUE OF TESTS; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RISK FACTORS; SEVERITY OF ILLNESS INDEX; SEX DISTRIBUTION; SEX FACTORS; SURVIVAL ANALYSIS;

EID: 33847214131     PISSN: 00365521     EISSN: 15027708     Source Type: Journal    
DOI: 10.1080/00365520600930750     Document Type: Article

References (41)

1. Loftus EV Jr, Schoenfeld P, Sandborn WJ. The epidemiology and natural history of Crohn's disease in population-based patient cohorts from North America: a systematic review. Aliment Pharmacol Ther 2002;16:51-60.
2. Wolters FL, Russel MG, Stockbrugger RW. Systematic review: has disease outcome in Crohn's disease changed during the last four decades? Aliment Pharmacol Ther 2004;20:483-96.
3. Munkholm P, Langholz E, Davidsen M, Binder V. Disease activity courses in a regional cohort of Crohn's disease patients. Scand J Gastroenterol 1995;30:699-706.
4. Thirlby RC, Land JC, Fenster LF, Lonborg R. Effect of surgery on health-related quality of life in patients with inflammatory bowel disease: a prospective study. Arch Surg 1998;133:826-32.
5. Casellas F, Lopez-Vivancos J, Badia X, Vilaseca J, Malagelada JR. Impact of surgery for Crohn's disease on health-related quality of life. Am J Gastroenterol 2000;95:177-82.
6. Lewis JD, Schwartz JS, Lichtenstein GR. Azathioprine for maintenance of remission in Crohn's disease: benefits outweigh the risk of lymphoma. Gastroenterology 2000;118:1018-24.
7. Faubion WA Jr, Loftus EV Jr, Harmsen WS, Zinsmeister AR, Sandborn WJ. The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study. Gastroenterology 2001;121:255-60.
8. Metge CJ, Blanchard JF, Peterson S, Bernstein CN. Use of pharmaceuticals by inflammatory bowel disease patients: a population-based study. Am J Gastroenterol 2001;96:3348-55.
9. Munkholm P, Langholz E, Davidsen M, Binder V. Frequency of glucocorticoid resistance and dependency in Crohn's disease. Gut 1994;35:360-2.
10. Silverstein MD, Loftus EV, Sandborn WJ, Tremaine WJ, Feagan BG, Nietert PJ, et al. Clinical course and costs of care for Crohn's disease: Markov model analysis of a population-based cohort. Gastroenterology 1999;117:49-57.
11. Podolsky DK. Inflammatory bowel disease. N Engl J Med 2002;347:417-29.
12. Sonnenberg A. Geographic variation in the incidence of and mortality from inflammatory bowel disease. Dis Colon Rectum 1986;29:854-61.
13. Garland CF, Lilienfeld AM, Mendeloff AI, Markowitz JA, Terrell KB, Garland FC. Incidence rates of ulcerative colitis and Crohn's disease in fifteen areas of the United States. Gastroenterology 1981;81:1115-24.
14. Shivananda S, Lennard Jones J, Logan R, Fear N, Price A, Carpenter L, et al. Incidence of inflammatory bowel disease across Europe: is there a difference between north and south? Results of the European Collaborative Study on Inflammatory Bowel Disease (EC-IBD). Gut 1996;39:690-7.
15. Stockbrugger R, Russel MG, BvM, Shivananda S. EC-IBD: a European effort in inflammatory bowel disease. Eur J Int Med 2000;11:187-90.
16. Lennard Jones JE. Classification of inflammatory bowel disease. Scand J Gastroenterol 1989; Suppl 170:2-6; discussion 16-9.
17. European Commission, Fifth Framework shared cost action (QLG4-CT-2000-01414). 2001-2005.
18. Wolters FL, Zeijl GV, Wessels F, Limonard C, Russel MGVM, Stockbrügger RW. Internet-based data inclusion in a European epidemiological follow-up study of IBD patients: a description of methods used. World J Gastroenterol 2005;11:7152-8.
19. Wolters FL, Russel MG, Sijbrandij J, Ambergen T, Odes S, Riis L, et al. Phenotype at diagnosis predicts recurrence rates in Crohn's disease. Gut 2006;55:1124-30.
20. Wolters FL, Russel MG, Sijbrandij J, Schouten LJ, Odes S, Riis L, et al. Crohn's disease: increased mortality 10 years after diagnosis in a Europe-wide population based cohort. Gut 2006;55:510-8.
21. Gasche C, Scholmerich J, Brynskov J, D'Haens G, Hanauer SB, Irvine EJ, et al. A simple classification of Crohn's disease: report of the Working Party for the World Congresses of Gastroenterology, Vienna 1998. Inflamm Bowel Dis 2000;6:8-15.
22. Singer J, Willet JB. Extending the Cox regression model. In: Applied longitudinal data analysis. Modelling range event occurrence. New York: Oxford University Press; 2003. pp 543-605.
23. Lunn M, McNeil D. Applying Cox regression to competing risks. Biometrics 1995;51:524-32.
24. Cleves M. Analysis of multiple failure-time data with stata. Stat Tech Bull 1999;49:340-47.
25. Steinhart AH, Girgrah N, McLeod RS. Reliability of a Crohn's disease clinical classification scheme based on disease behavior. Inflamm Bowel Dis 1998;4:228-34.
26. Riis L, Munkholm P, Binder V, Candstat LT, Langholz E. Intra- and interobserver variation in the use of the Vienna classification of Crohn's disease. Inflamm Bowel Dis 2005;11:657-61.
27. Lennard Jones JE, Shivananda S. Clinical uniformity of inflammatory bowel disease at presentation and during the first year of disease in the north and south of Europe. ECIBD Study Group. Eur J Gastroenterol Hepatol 1997;9:353-9.
28. Vind I, Riis L, Jess T, Knudsen E, Pedersen N, Elkjaer M, et al. Increasing incidences of inflammatory bowel disease and decreasing surgery rates in Copenhagen City and County, 2003-2005: a population-based study from the Danish Crohn colitis database. Am J Gastroenterol 2006;101:1274-82.
29. Fernandez E, Schiaffino A, Borras JM, Shafey O, Villalbi JR, La Vecchia C. Prevalence of cigarette smoking by birth cohort among males and females in Spain, 1910-1990. Eur J Cancer Prev 2003;12:57-62.
30. Kemm JR. A birth cohort analysis of smoking by adults in Great Britain 1974-98. J Public Health Med 2001;23:306-11.
31. Brenner H. A birth cohort analysis of the smoking epidemic in West Germany. J Epidemiol Community Health 1993;47:54-8.
32. Colombo P, Scarpino V, Zuccaro P, Apolone G, Gallus S, La Vecchia C. Smoking in Italian women and men, 2001. Tumori 2002;88:10-2.
33. Mawdsley JE, Rampton DS. Psychological stress in IBD: new insights into pathogenic and therapeutic implications. Gut 2005;54:1481-91.
34. Elliott DE, Urban JJ, Argo CK, Weinstock JV. Does the failure to acquire helminthic parasites predispose to Crohn's disease? Faseb J 2000;14:1848-55.
35. Miura S, Tsuzuki Y, Hokari R, Ishii H. Modulation of intestinal immune system by dietary fat intake: relevance to Crohn's disease. J Gastroenterol Hepatol 1998;13:1183-90.
36. Ekbom A, Helmick CG, Zack M, Holmberg L, Adami HO. Survival and causes of death in patients with inflammatory bowel disease: a population-based study. Gastroenterology 1992;103:954-60.
37. Mayberry JF, Newcombe RG, Rhodes J. Mortality in Crohn's disease. Q J Med 1980;49:63-8.
38. Louis E, Collard A, Oger AF, Degroote E, Aboul Nasr El Yafi FA, Belaiche J. Behaviour of Crohn's disease according to the Vienna classification: changing pattern over the course of the disease. Gut 2001;49:777-82.
39. Cosnes J, Cattan S, Blain A, Beaugerie L, Carbonnel F, Parc R, et al. Long-term evolution of disease behavior of Crohn's disease. Inflamm Bowel Dis 2002;8:244-50.
40. Polito JM, 2nd, Childs B, Mellits ED, Tokayer AZ, Harris ML, Bayless TM. Crohn's disease: influence of age at diagnosis on site and clinical type of disease. Gastroenterology 1996;111:580-6.
41. Cottone M, Rosselli M, Orlando A, Oliva L, Puleo A, Cappello M, et al. Smoking habits and recurrence in Crohn's disease. Gastroenterology 1994;106:643-8.